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INTRODUCTION
Sickle-cell diseases (SCD) constitute a group of hereditary 
anemias that occur together with chronic hemolytic anemia, 
vasculopathy, vaso-occlusive phenomena, and acute and 
generalized chronic organ lesion. One of these diseases is 
sickle-cell anemia, a recessive autosomal disease that results 
from a mutation in the beta (ß) globin (chromosome 11), 
originating hemoglobin S, of which its homozygous form 
characterizes this pathology. 
According to the World Health Organization (WHO), 
there are approximately 20 million individuals with sickle-
cell anemia worldwide. Although SCD are more common 
in Africa, the migratory flows have disseminated the gene 
around the world1. 
Although the physiopathology of vaso-occlusion is not 
completely understood, it is known that the interactions be-
tween sickled red blood cells, endothelial alterations, vascu-
lar muscle tonus deregulation, activation of monocytes and 
adhesion molecules secondary to frequent hemolysis have 
an important role in the development of the disorder. 
Certain complications such as cerebrovascular accident, 
pulmonary hypertension, priapism and leg ulcers are re-
lated to the intensity of hemolysis, whereas painful crises, 
acute chest syndrome (ACS) and osteonecrosis are associ-
ated with the high blood viscosity and the interactions be-
tween sickle cells, leukocytes and endothelium. 
Due to the high morbidity and elevated complication 
treatment costs, there is an interest regarding the study of 
new therapies, such as the therapeutic use of inhaled nitric 
oxide.  
Nitric oxide (NO) is a vasodilating substance, in addi-
tion to inhibiting platelet aggregation, decreasing cell adhe-
sion molecules and also modulating ischemic lesions with 
reperfusion. 
The objective of this systematic review was to evaluate 
the safety and effectiveness of inhaled NO to treat vaso-oc-
clusive crises in sickle-cell anemia.  
METHODS
A systematic review was carried out in the MEDLINE da-
tabase using the following search strategy: (Anemia, Sickle 
Cell OR Acute Chest Syndrome) AND Nitric Oxide. The 
filter “Therapy/Narrow” was used through the Clinical 
Queries interface. The authors analyzed the studies inde-
pendently by title and summary of each recovered article 
and selected those that met the inclusion criteria: random-
ized clinical assay comparing the use of nitric oxide with 
placebo that had been written in Portuguese, English or 
Spanish. 
After this initial selection process, the authors read the 
full text of the eligible articles and evaluated them criti-
cally. Only studies with a score ≥ 3 according to the cri-
teria established by Jadad et al.2 were included in the data 
analysis.  
To evaluate effectiveness, we used the differences in 
mean time until crisis resolution between the groups and 
the decrease in the mean pain score according to the Vi-
sual Analog Scale (VAS), after 24 hours.
As a safety parameter, we used the difference between 
the frequency of adverse events and the acute chest syn-
drome (ACS) within 72 hours and the rate of return to 
the ER and re-hospitalization after 30 days. The measure 
used was the absolute risk reduction (ARR) with the corre-
sponding 95% confidence interval (95% CI) and the num-
ber necessary to treat (NNT). 
The t test was used to analyze the continuous variables 
(for difference of means), with the OpenEpi online tool 
and the Chi-square test was used to analyze dichotomous 
variables, with the Catmaker software. 
RESULTS
The literature review was finished on March 07, 2011. A 
total of 124 articles were found, of which only three3-5 met 
the inclusion criteria. After careful reading and analysis of 
these three eligible articles, two were excluded for having 
losses to follow-up >  20%4,5. The only eligible article se-
lected was the study by Gladwin et al.3, which had a score 
of 4 according to Jadad et al.2.
The data of that study demonstrated there was no sig-
nificant difference in resolution time of vaso-occlusive 
crisis between the two groups. The study p-value for the 
differences in medians was 0.87.
The study did not disclose the data on the time differ-
ence regarding crisis resolution as means and standard 
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Outcome Nitric oxide Placebo p-value
Crisis resolution (hours) 73 (46.0 to 91.0) 65.5 (48.1 to 84.0) 0.60/0.33
VAS score 24 hours (cm) 6.1 (5.3 to 6.8) 6.0 (5.4 to 6.6) 0.92
Table 1 
Outcome Nitric oxide Placebo ARR (95% CI) NNT
Adverse events 9 6 - 0.040 (-0.136 to 0.056) -25
Return to the ER 8 11 0.04 (-0.066 to 0.146) 25
Rehospitalization 9 17 0.107 (- 0.013 to 0.227) 9
ACS 5 5 0
Table 2 
deviations, as these data are usually expressed, but as me-
dians with 95% CI, of which upper and lower limits were 
not equidistant from the median. Therefore, the authors 
calculated the one-sided p value in two different ways: us-
ing the upper limits and the lower limits of the 95% CI. 
The values obtained were 0.60 and 0.33, respectively.
All the other parameters (VAS mean score, adverse 
events, acute chest syndrome, return to the ER and re-
hospitalization) also demonstrated non-significant differ-
ences, as shown in Tables 1 and 2. 
EVIDENCE SYNTHESIS
The use of inhaled nitric oxide for the treatment of vaso-
occlusive crises in sickle-cell anemia does not demonstrate 
any significant differences regarding benefits or damages, 
when compared to the conventional treatment.
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